... PharmaMar in Madrid (Spain) has a bit of a different approach to drug discovery. It researches compounds present inmarine organisms to assess if they have biological action against tumor cells.
After a market filing last month for its candidate Aplidin, PharmaMar has now presented data from Phase I trials of Aplidin in combination with chemotherapy (bortezomib anddexamethasone) in patients with relapsed and/or refractory multiple myeloma.
The treatment was well tolerated by the 20 patients, and it had an overall response rate of 56% – including a partial remission in a patient whose cancer had reappeared 3 times after treatment.
...
...